Mycoplasma pneumoniae-associated mucositis with minimal skin manifestations

American Journal of Clinical Dermatology

Volumn 9, Issue 6, 2008, Pages 399-403

  Figueira Coelho, João ^a,b   Lourenço, Sofia ^a   Pires, Ana Cristina ^a   Mendonça, Paula ^a   Malhado, José António ^a  

^a HOSPITAL CURRY CABRAL   (Portugal)

^b NONE   (Portugal)

Author keywords

Levofloxacin, therapeutic use; Mucositis, treatment; Prednisolone, therapeutic use; Skin infections

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; EYE OINTMENT; FLURBIPROFEN; GENTAMICIN; HYDROGEN PEROXIDE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M; IMMUNOGLOBULIN M ANTIBODY; LEVOFLOXACIN; NORFLOXACIN; NYSTATIN; PETROLATUM; PREDNISOLONE;

ADULT; ANTIBODY TITER; ARTICLE; CASE REPORT; CONJUNCTIVITIS; COUGHING; DYSPNEA; EMERGENCY WARD; FEVER; HEADACHE; HUMAN; LABORATORY TEST; MALE; MOUTH ULCER; MUCOSA INFLAMMATION; MYALGIA; MYCOPLASMA PNEUMONIAE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SCROTUM DISORDER; SKIN MANIFESTATION; TONGUE ULCER; TREATMENT FAILURE; TREATMENT RESPONSE; VEIN PUNCTURE;

ADULT; ANTI-BACTERIAL AGENTS; ASTHMA; CONJUNCTIVITIS; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUNG; MALE; MUCOSITIS; MYCOPLASMA INFECTIONS; MYCOPLASMA PNEUMONIAE; OFLOXACIN; PREDNISOLONE; RADIOGRAPHY, THORACIC; SKIN ULCER;

EID: 55249104772     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/0128071-200809060-00008     Document Type: Article

References (38)

1. Alter SJ, Stringer B. Mycoplasma pneumoniae infections associated with severe mucositis. Clin Pediatr 1990; 10: 602-4
2. Barfod TS, Pedersen C. Severe stomatitis caused by Mycoplasma pneumoniae infection. Ugeskr Laeger 1999; 161: 6363-4
3. Deborah F, Hesketh EL, Mitchell AE, et al. Mycoplasma pneumoniae infection complicated by pneumomediastinum and severe mucositis. J Pediatr Child Health 2007; 43: 403-5
4. Kirke S, Powell FC. Mucosal erosions and a cough. Ir Med J 2003; 96: 245
5. Ravin KA, Rappaport LD, Zuckerbraun NS, et al. Mycoplasma pneumoniae and atypical Stevens-Johnson syndrome: a case series. Pediatrics 1997; 119: e1002-5
6. Schalock PC, Dinulos JGH. Mycoplasma pneumoniae-induced Stevens Johnson syndrome without skin lesions: fact or fiction? J Am Acad Dermatol 2005; 52: 312-5
7. Sieber OF, John J, Fulginiti VA, et al. Stevens-Johnson syndrome associated with Mycoplasma pneumoniae infection. JAMA 1967; 200: 79-81
8. Vanfleteren I, Van Gysel D, de Brandt C. Stevens-Johnson syndrome: a diagnostic challenge in the absence of skin lesions. Pediatr Dermatol 2003; 20: 52-6
9. Latsch K, Girschick HJ, Abele-Horn M. Stevens Johnson syndrome without skin lesions. J Med Microbiol 2007; 56: 1696-9
10. Eaton MD, Meiklejohn G, Van Herick W. Studies on the etiology of primary atypical pneumonia: a filterable agent transmissible to cotton rats, hamsters, and chick embryos. J Exp Med 1944; 79: 649-67
11. Chanock RM, Hayflick L, Barile MF. Growth on artificial medium of agent associated with atypical pneumonia and its identification as a PPLO. Proc Natl Acad Sci U S A 1962; 48: 41-9
12. Chanock RM, Dienes L, Eaton MD. Mycoplasma pneumoniae: proposed nomenclature for atypical pneumonia organism (Eaton agent). Science 1963; 140: 662
13. Blasi F, Tarsia P, Aliberti A, et al. Chlamydia pneumoniae and Mycoplasma pneumoniae. Sem Respir Crit Care Med 2005; 26: 617-24
14. Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev 2004; 17: 697-728
15. Cimolai N, Wensley D, Seear M, et al. Mycoplasma pneumoniae as a cofactor in severe respiratory infections. Clin Infect Dis 1995; 21: 1182-5
16. Nadala D, Bossart W, Zucol F, et al. Community-acquired pneumonia in children due to Mycoplasma pneumoniae: diagnostic performance of a seminested 16S rDNA-PCR. Diagn Microbiol Infect Dis 2001; 39: 15-9
17. Souliou E, Almasri M, Papa A, et al. Laboratory diagnosis of Mycoplasma pneumoniae respiratory tract infections in children. Eur J Clin Microbiol Infect Dis 2007; 26: 513-5
18. Thacker WL, Talkington DF. Analysis of complement fixation and commercial enzyme immunoassays for detection of antibodies to Mycoplasma pneumoniae in human serum. Clin Diagn Lab Immunol 2000; 7: 778-80
19. Waris ME, Toikka P, Saarinen T, et al. Diagnosis of Mycoplasma pneumoniae pneumonia in children. J Clin Microbiol 1998; 36: 3155-9
20. Putman CE, Curtis AM, Simeone JF, et al. Mycoplasma pneumoniae: clinical and roentgenographic patterns. Am J Roentgenol Radium Ther Nucl Med 1975; 124: 417-22
21. Lee I, Kim TS, Yoon H. Mycoplasma pneumoniae pneumonia: CT features in 16 patients. Eur Radiol 2006; 16: 719-25
22. Okada F, Ando Y, Wakisaka M, et al. Chlamydia pneumoniae pneumonia and Mycoplasma pneumoniae pneumonia: comparison of clinical findings and CT findings. J Comput Assist Tomogr 2005; 29: 626-32
23. Stevens AM, Johnson FC. A new eruptive fever associated with stomatitis and ophthalmia. Am J Dis Child 1922; 24: 526-33
24. Lind K. Mucocutaneous reactions during Mycoplasma pneumoniae infection. Lancet 1978; I: 655
25. Sontheimer RD, Garibaldi RA, Krueger GG. Stevens-Johnson syndrome associated with Mycoplasma pneumoniae infections. Arch Dermatol 1978; 114: 241-4
26. Stanyon JH, Warner WP. Mucosal respiratory syndrome. Can Med Assoc J 1945; 53: 427-34
27. Huff JC, Weston WL, Tonnesen MG. Erythema multiforme: a critical review of characteristics, diagnostic criteria and causes. J Am Acad Dermatol 1983; 8: 763-75
28. Lucier TS, Heitzman K, Liu SK, et al. Transition mutations in the 23S rRNA of erythromycin-resistant isolates of Mycoplasma pneumoniae. Antimicrob Agents Chemother 1995; 39: 2770-3
29. Matsuoka M, Narita M, Okazaki N, et al. Characterization and molecular analysis of macrolide-resistant Mycoplasma pneumoniae: clinical isolates obtained in Japan. Antimicrob Agents Chemother 2004; 48: 4624-30
30. Cheriyan S, Patterson R, Greenberger PA, et al. The outcome of Stevens-Johnson syndrome treated with corticosteroids. Allergy Proc 1995; 16: 151-5
31. Patterson R, Grammer LC, Greenberger PA, et al. Stevens-Johnson syndrome (SJS): effectiveness of corticosteroids in management and recurrent SJS. Allercomgy Proc 1992; 12: 89-95
32. Patterson R, Miller M, Kaplan M, et al. Effectiveness of early therapy with corticosteroids in Stevens-Johnson syndrome: experience with 41 cases and ashypothesis regarding pathogenesis. Ann Allergy 1994; 73: 27-34
33. Tripathi A, Ditto AM, Grammer LC, et al. Corticosteroid therapy in an additional 13 cases of Stevens-Johnson syndrome: a total series of 67 cases. Allergy Asthma Proc 2000; 21: 101-5
34. Mittmann N, Chan B, Knowles S, et al. Intravenous immunoglobulin use in patients with toxic epidermal necrolysis and Stevens-Johnson syndrome. Am J Clin Dermatol 2006; 7: 359-68
35. Zipitis CS, Thalange N. Intravenous immunoglobulins for the management of Stevens-Johnson syndrome with minimal skin manifestations. Eur J Pediatr 2007; 166: 585-8
36. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 2003; 139: 33-6
37. Brett AS, Philips D, Lynn AW. Intravenous immunoglobulin therapy for Stevens-Johnson syndrome. South Med J 2001; 94: 342-3
38. Prins C, Vittorio C, Padilla RS, et al. Effect of high-dose intravenous immunoglobulin therapy in Stevens-Johnson syndrome: a retrospective, multicenter study. Dermatology 2003; 207: 96-9